1 citations
,
June 2025 in “Asian Journal of Medical Sciences” In this study, MMF plus prednisolone was found to induce remission in 81% of patients with proliferative lupus nephritis, with fewer adverse effects such as alopecia and amenorrhea compared to CYC plus prednisolone, despite similar overall remission rates.
137 citations
,
December 2006 in “Arthritis Research & Therapy” This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.
2 citations
,
January 2012 in “PubMed” This study found that mycophenolate mofetil is effective for both induction and maintenance therapy in children with severe lupus nephritis, significantly improving proteinuria and antibody levels, without renal flares during maintenance.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” This study concluded that a sequential regimen of prednisolone and cyclophosphamide, followed by low-dose prednisolone and azathioprine, achieved favorable results in most patients with diffuse proliferative and/or membranous lupus nephritis without significant toxicities.
12 citations
,
November 1996 in “Australasian journal of dermatology” A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.